Denosumab use reduces risk of rheumatoid arthritis in patients with osteoporosis

CONCLUSIONS: Denosumab use reduces the risk of RA in patients with osteoporosis. Receptor activator of nuclear factor kappa B ligand (RANKL) mediated osteoclast joint damage may be involved in the pathogenesis of RA during the preclinical stage.PMID:38179713 | DOI:10.55563/clinexprheumatol/3ohsj3

Source: Clinical and Experimental Rheumatology - January 5, 2024 Category: Rheumatology Authors: Chun-Hsiung Chen Hsien-Tzung Liao Hung-An Chen Yi-Ning Yen Chen-Hung Chen Source Type: research